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Tumor-suppressor activity of RRIG1 in breast
cancer
Guihong Zhang1,3, Abenaa Brewster1, Baoxiang Guan1, Zhen Fan2, Powel H Brown1, Xiao-Chun Xu1,3*
Abstract
Background: Retinoid receptor-induced gene-1 (RRIG1) is a novel gene that has been lost in several types of
human cancers. The aim of this study was to determine whether RRIG1 plays a role in breast cancer, such as in the
suppression of breast cancer cell growth and invasion.
Methods: Immunohistochemistry was used to detect RRIG1 expression in breast tissue specimens. Gene
transfection was used to restore or knock down RRIG1 expression in breast cancer cell lines for analysis of cell
viability, colony formation, and migration/invasion potential. Reverse-transcription polymerase chain reaction and
western blot assays were used to detect the changes in gene expression. The RhoA activation assay was used to
assess RRIG1-induced inhibition of RhoA activity.
Results: The immunohistochemical data showed that RRIG1 expression was reduced in breast cancer tissues
compared with normal and atypical hyperplastic breast tissues. RRIG1 expression was inversely correlated with
lymph node metastasis of breast cancer but was not associated with the status of hormone receptors, such as
estrogen receptor, progesterone receptor, or HER2. Furthermore, restoration of RRIG1 expression inhibited
proliferation, colony formation, migration, and invasion of breast cancer cells. Expression of RRIG1 also reduced
phosphorylated Erk1/2 and Akt levels; c-Jun, MMP9, and Akt expressions; and RhoA activity. In contrast, knockdown
of RRIG1 expression promoted breast cancer cell proliferation, colony formation, migration, and invasion potential.
Conclusion: The data from the current study indicated that RRIG1 expression was reduced or lost in breast cancer
and that restoration of RRIG1 expression suppressed breast cancer cell growth and invasion capacity. Future studies
will determine the underlying molecular mechanisms and define RRIG1 as a tumor-suppressor gene in breast
cancer.
Background
Breast cancer is the leading cause of cancer-related
death in women between 35 and 45 years of age and
remains the second-leading cause of cancer-related
death among all women in the United States [1]. Despite
success in screening for early stages of breast cancer and
remarkable improvement in treatment outcomes, many
women still develop metastatic disease and ultimately
die [2-4]. Efforts for ultimate elimination of this disease
should include an emphasis on 1) a better understand-
ing of breast cancer biology, including elucidation of the
functions of the genes involved in breast cancer devel-
opment, progression, and metastasis; 2) development of
novel biomarkers for early detection, pretreatment sta-
ging, prediction of response to treatments, monitoring
disease progression, and prognosis of breast cancer; and
3) innovative approaches for treatment and prevention
of breast cancer.
Our group recently identified and cloned a novel reti-
noid receptor-induced gene, RRIG1 [5-8]. We found that
the RRIG1 gene covers 4.181 kb of genomic sequences
and is localized at chromosome 9q34 with 6 exons, cod-
ing a protein with 276 amino acids. RRIG1 mRNA is
expressed in a broad range of normal tissues, but its
expression is lost in various types of cancers, including
breast cancer [5,6]. RRIG1 mediates the effect of RAR-b2
on gene expression (e.g., Erk1/2 and COX-2) and cell
growth. RRIG1 expression was found to be correlated
with tumor differentiation but inversely correlated
with lymph node metastasis of esophageal cancer [6].
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Furthermore, the transient and stable transfection of a
RRIG1 expression vector resulted in growth inhibition of
esophageal and prostate cancer cells [5,6,8]. Esophageal
cancer cells transfected with RRIG1 also showed reduced
tumorigenicity in nude mice [6]. These data strongly
indicate that RRIG1 plays an important role in suppres-
sing the development or progression of human cancers
[5,6,8]. At the level of signal transduction, expression of
RRIG1 inhibited Src phosphorylation and RhoA activa-
tion, which is believed to be causally linked to reduced
colony formation, invasion, and proliferation in esopha-
geal and prostatic cancer cells. In contrast, transfection
of antisense RRIG1 increased RhoA activity and f-actin
formation and led to increased colony formation, inva-
sion, and proliferation in these cells [5,8].
In this study, we first determined the correlation of
RRIG1 expression in breast tissue specimens with the
clinicopathologic characteristics of the patients and then
examined the effect of RRIG1 expression on breast can-
cer growth and invasion. We also explored the changes
in expression and phosphorylation or activation of sev-
eral relevant proteins following experimental elevation
or knockdown of RRIG1 expression in breast cancer
cells. Our data indicate that RRIG1 may function as a
tumor-suppressor gene in breast cancer.
Methods
Immunohistochemistry
Paraffin blocks from breast tissue specimens were
obtained from the Department of Pathology, Anhui
Medical University, Hefei, China, guided by a protocol
(#Lab08-015) approved by the institutional review
board. Patients gave consent for the use of their tissue
specimens in this study. These tissue specimens con-
sisted of samples from 15 normal mammary glands, 9
atypical hyperplasia lesions, 10 cases of ductal carcinoma
in situ, and 77 cases of invasive breast cancer. For
immunohistochemical analysis, these paraffin sections
together with paraffin sections from the organotypic cul-
tures were prepared and stained for RRIG1 as previously
reported [6]. Briefly, the tissue sections were deparaffi-
nized twice in xylene for 10 min each and rehydrated in
a series of ethanol (100%-50%) and then subjected to
antigen retrieval with 0.01 M citric buffer in a pressure
cooker for 5 min, followed by blocking of tissue endo-
genous peroxidase activity with H2O2 treatment. The
processed tissue sections were then incubated with 100
μL of 20% normal goat serum in phosphate-buffered sal-
ine (PBS) and anti-RRIG1 antibody (custom-made by
Lampire Biological Laboratories, Pipersville, PA, with
the CAADGLRKPQVHSARAL peptide as the antigen)
at 1:500 dilutions with PBS overnight. The next day, the
sections were gently washed three times with PBS and
once with PBS containing 0.1% Tween 20. They were
then subjected to sequential incubations with a second
antibody (goat anti-rabbit IgG; Vector Laboratories, Bur-
lingame, CA) and the ABC solution (in the dark) for 30
min each, with washing between incubations to remove
unbound antibodies. The sections were subject to color
development with 9-ethylcarbazol-3-amine for 15 min
and counterstained with hematoxylin for 1 min. After
being covered with a cover slip, the sections were
viewed and scored under a microscope. A semiquantita-
tive scoring system was used to score both the staining
intensity and the percentage of staining in the tissue
sections. The staining intensity was scored as follows: 0,
no staining; +, weak staining; ++ positive staining; and +
++, very strong staining. The percentage of staining was
scored as follows: 0, no staining; +, less than 10% of
tumor cells stained; ++, 10-50%; and +++, more than
50% tumor cells stained positive. Both intensity and per-
centage of staining with 0 or + were considered as nega-
tive cases, while both intensity and percentage of
staining with ++ and +++ were considered as positive
cases.
Cell lines and culture
The human breast cancer cell lines MCF-7, MDA-MB-
231, T47D, SK-Br-3, ZR75-1, and MDA-MB-435 were
obtained from ATCC (Manassas, VA) and grown in
Dulbecco’s modified Eagle’s minimal essential medium
(DMEM), supplemented with 10% fetal bovine serum,
at 37ºC in a humidified atmosphere of 95% air and
5% CO2. Esophageal cancer TE-8, the stably RAR-b2-
transfected TE-8S22, stably RRIG1-transfected TE-8-
RRIG1 cells, and prostate cancer PC3 cells were from
our previous study [5]. These cell lines were grown in
Dulbecco’s modified Eagle’s minimal essential medium
(DMEM), supplemented with 10% fetal bovine serum, at
37ºC in a humidified atmosphere of 95% air and 5%
CO2. The growth medium for the stable gene trans-
fected cells also contained 200 μg/ml G418 (Invitrogen,
Carlsbad, CA).
RRIG1 expression vector and transient gene transfection
RRIG1 sense and antisense open-reading frames were
inserted into pCDNA3.1 plasmid as reported in our pre-
vious studies [5,6]. The plasmids were used for transient
transfection into MDA-MB-231, MDA-MB-435, and
T47D with FuGENE 6 (Roche Diagnostics, Indianapolis,
IN) or Lipofectamine™ 2000 (Invitrogen). Thirty-six
hours after the transfection, the cells were selected with
1200 μ g/mL G418 (Invitrogen) for 5 days. The total
cellular protein was extracted from the cells and sub-
jected to Western blotting analysis. In duplicate experi-
ments, RNA was extracted from the cells and subjected
to semiquantitative reverse transcription-polymerase
chain reaction (RT-PCR) analysis of gene expression as
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described previously [6,7]. After preliminary investiga-
tion to determine the optimal number of PCR cycles
(between 25 and 34), we used 32 cycles of PCR to
amplify RRIG1 mRNA. GAPDH was used as a loading
control. The primers for RRIG1 mRNA were 5’-
CTCCCAGGGTGCCATATTT-3’ and 5’-GTCATA-
GAGCACCCGAGCTT-3’, which generated a 211-bp
band. The primers for MMP-9 expression were 5’-
GCACGACGTCTTCCAGTACC-3’ and 5’-GTTTGTAT
CCGGCAAACTGG-3’, which generated a 224-bp band.
The primers for SH3GLB2 expression were 5’-GCAGA-
CAGCACCAAGAACTG-3’ and 5’-TTTTCAGCTT
CTGCCACCTT-3’, which generated a 233-bp band.
GAPDH primers were 5’-CCCTTCATTGACCTCAAC-
TACATGG-3’ and 5’-CATGGTGGTGAAGACGCCAG-
3’, which generated a 192-bp band.
MTT assay
The cells were grown and transiently transfected with
RRIG1 sense or antisense cDNA and then grown in
G418-containing medium for 1 or 5 days. For the
methyl thiazolyl tetrazolium (MTT) assay, 20 μL of
MTT (5 mg/ml, Sigma, St. Louis, MO) was added to
each well of the 96-well plates and incubated for an
additional 4 h. After the growth medium was removed,
100 μL of dimethyl sulfoxide was added to the wells to
dissolve the MTT crystal, and the optical densities were
measured with an automated spectrophotometric plate
reader at a single wavelength of 540 nm. The percentage
of cell growth was calculated using the formula: % con-
trol = ODt/ODc × 100, where ODt and ODc are the
optical densities for transfected and vector control cells,
respectively.
Colony formation assay
The ability of cells to form colonies in soft agarose is
indicative of anchorage independence and is used as an
in vitro criterion of transformation. We examined
whether these cells can form colonies in soft agar after
gene transfection [9]. Briefly, 2 × 103 gene-transfected
cells were mixed in low-temperature-melting agarose
(0.35%) and then placed on top of solidified agarose in
60-mm-diameter dishes. After the top agarose with cells
solidified in the cold room for 15 min, the dishes were
incubated in a humidified atmosphere of 95% air and
5% CO2 at 37°C for 21 days. At the end of the experi-
ments, the colonies were visualized by incubation with
MTT at 37°C for 4 h and counted under an inverted
microscope at 40× magnification.
Migration and invasion assay
Boyden chambers coated with and without Matrigel
(obtained from BD Biosciences, Bedford, MA) were used
for assaying tumor cell invasion and migration ability,
respectively [5]. The transfected cells were first starved
in medium without fetal calf serum (FCS) overnight,
and the cells (5 × 104) were resuspended in the FCS-
free medium and put into the top chambers in triplicate.
The lower chamber was filled with 10% FCS as the che-
moattractant and incubated for approximately 24 h for
the migration assay and 48 h for the invasion assay. The
surface was then wiped with a cotton swab to remove
the cells on the upper surface. The cells that invaded
the Matrigel and attached to the lower surface of the fil-
ter were fixed and stained with 1% crystal violet solu-
tion. The membranes with or without Matrigel were
then gently removed from the chamber and mounted
on glass slides. Six microscopic fields (at 100× magnifi-
cation) per chamber were photographed. The cells in
the photographs were then counted, and the data were
summarized as means ± standard deviation and pre-
sented as the percentage of control. Student t-test was
used to determine statistical differences between the
control and RRIG1 sense- or antisense-transfected
breast cancer cells.
Protein extraction and western blotting
Total cellular protein was isolated from the gene-trans-
fected breast cancer cells as described previously [5-7].
The protein concentration was then measured with a
Bio-Rad Protein Assay Kit II (BioRad Laboratories, Her-
cules, CA) according to the manufacturer’s protocol.
Samples containing 50 μg of protein from control or
treated cells were separated by 10-14% polyacylamide
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis gels and then transferred electrophoretically to a
Hybond-C nitrocellulose membrane (GE-Healthcare,
Arlington Heights, IL) at 500 mA for 2 h at 4°C. The
membrane was subsequently stained with 0.5% Ponceau
S (Sigma) containing 1% acetic acid to confirm that pro-
teins were loaded equally and to verify transfer effi-
ciency. The membranes were next incubated overnight
in a blocking solution containing 5% bovine skim milk
and 0.1% Tween 20 in PBS at 4°C. The next day, the
membranes were incubated with primary antibodies for
2 h at room temperature. The antibodies used were
anti-p-Erk1/2, t-Erk1/2, p-Akt, t-Akt, p-Stat3, t-Stat3, p-
Rb, and Rb (Cell Signaling Technology, Beverly, MA);
anti-c-Jun and E2F-1 (Santa Cruz Biotechnology, Santa
Cruz, CA); and anti-b-actin (Sigma). The membranes
were washed in PBS and incubated for 1.5 h with horse-
anti-mouse or goat-anti-rabbit secondary antibody (GE-
Healthcare) diluted 1:5000. The membranes were then
incubated with enhanced chemiluminescence solution
(GE-Healthcare) for 1-2 min and exposed to X-ray film.
The target band of proteins from western blots was
quantified by using NIH ImageJ 1.34s software (NIH,
Bethesda, MD) and normalized to b-actin. After that,
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the percentage of control was calculated using the for-
mula: value of the RRIG1 sense or antisense transfected
cells/value of the vector-only transfected cells.
RhoA activation assay
The RRIG1 sense and antisense cDNA-transfected
breast cancer cells were detached with 0.05% trypsin,
counted, reseeded, and cultured in new dishes in
DMEM with 10% FCS for 16 hours and then in DMEM
without FCS for an additional 12 hours. To activate
RhoA, the cells were cultured in DMEM with 10% FCS
for 6 h, and the total cellular protein was extracted in
an ice-cold lysis buffer containing 20 mM Tris-HCl (pH
7.5), 10 mM MgCl2, 150 mM NaCl, 1 mM Na2EDTA, 1
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyropho-
sphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, and
1 μg/ml leupeptin. Activated GTP-bound Rho protein in
the cell lysates was pulled down using a recombinant
GST-tagged Rhotekin Rho-binding domain (Millipore,
Billerica, MA) and analyzed in western blots using anti-
RhoA antibody (Santa Cruz Biotechnology). Levels of
the activated RhoA protein were normalized with the
total cell lysates that were not subjected to the pulldown
assay.
Results
Immunohistochemical analysis of RRIG1 expression in
breast tissue specimens
In this study, we first verified the specificity of our rab-
bit polyclonal anti-RRIG1 antibody using three different
experiments. Briefly, we first performed western blot
with this antibody to detect expression of RRIG1 protein
in vitro translated with an in vitro translation kit from
Promega (Madison, WI). The data showed that this anti-
body specifically recognized RRIG1 protein (Additional
Figure S1a). Meanwhile, in two different cancer cell
lines we detected RRIG1 expression, which had been
established by Northern blot in our previous study. We
found that RRIG1-positive esophageal cancer cell line
TE-8S22 expressed RRIG1 protein, whereas the PC3
cells did not show the target band, although the western
blot showed a number of nonspecific bands (Additional
Figure S1b), indicating that this antibody is not suitable
for western blot assay.
To determine whether this antibody could be used for
immunohistochemistry, we compared the data between
immunohistochemistry and in situ hybridization for
expression of RRIG1 mRNA and protein in the matched
cells and tissues (Additional Figure S1cd). These data
suggest that this antibody is suitable for immunohisto-
chemistry. Next, we used immunohistochemical analysis
to determine the RRIG1 expression in breast tissue spe-
cimens and found that RRIG1 was expressed in 14 of 15
normal mammary glands, 8 of 9 cases of atypical
hyperplasia of the mammary gland, 6 of 10 ductal carci-
noma in situ tissues, and 50 of 77 invasive breast cancer
tissues (P = 0.023 between normal and invasive cancer
by Fisher exact test) (Figure 1).
Finally, we associated RRIG1 expression with the clini-
copathologic features of the breast cancer patients and
found a statistically significant reverse correlation
between RRIG1 expression and lymph node metastasis
in breast cancer (Table 1).
RRIG1 regulation of breast cancer cell growth, migration,
and invasion
We then detected expression of RRIG1 mRNA in 6 dif-
ferent breast cancer cell lines using semiquantitative RT-
PCR and found that MDA-MB-435 and T47D expressed
high levels of RRIG1 mRNA and that MCF-7 and SK-Br3
expressed low levels of RRIG1 mRNA. In contrast,
MDA-MB-231 and ZR75-1 did not express RRIG1
mRNA (Figure 2A). Given these findings, we chose
MDA-MB-231 and MDA-MB-435 for modulation of
RRIG1 expression to assess the changed cell behaviors
and gene expression. We transiently transfected RRIG1
sense and antisense cDNAs into the MDA-MB-231 and
MDA-MB-435 cell lines, respectively. After gene trans-
fection, RRIG1 expression was knocked down by RRIG1
antisense vector in MDA-MB-435 cells, while RRIG1
cDNA transfection restored RRIG1 expression in MDA-
MB-231 cells (Figure 2B). Next, we used the MTT assay
to detect the changed cell viability by RRIG1 and found
that restoration of RRIG1 expression reduced cell viabi-
lity in MDA-MB-231 cells, but knockdown of RRIG1
expression induced cell viability in MDA-MB-435 cells
after 5 d of cultures (Figure 2C). Furthermore, RRIG1
expression decreased the number of colonies in MDA-
MB-231 cells, and knockdown of RRIG1 expression in
MDA-MB-435 cells increased the numbers of colonies in
soft agar (Figure 2D). In addition, our data also showed
that RRIG1 decreased migration and invasion capacity of
MDA-MB-231 cells but increased the migratory and
invasion capacity of MDA-MB-435 cells (Figure 3).
RRIG1 regulation of gene expression in breast cancer cells
To determine the underlying molecular events of RRIG1
in the inhibition of breast cancer cell proliferation, migra-
tion and invasion, we performed semiquantitative RT-PCR
and western blotting analysis to assess RRIG1 regulation
of gene expression and the RhoA activation assay to detect
the changed RhoA activity. We found that RRIG1 expres-
sion downregulated p-Erk1/2, p-AKT, total AKT, c-Jun,
and MMP9 expression in MDA-MB-231 cells, whereas
knockdown of RRIG1 expression upregulated p-AKT,
total AKT, p-Stat3, p-RB, and E2F-1 expression in MDA-
MBN-435 cells (Figure 4). However, these data demon-
strated that RRIG1 sense and antisense cDNAs regulated
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expression of different genes, indicating that different
breast cancer cell lines may have different gene alterations
and that RRIG1 can regulate expression of some of them
for control of breast cancer cell proliferation, migration,
and invasion. Furthermore, we confirmed that RRIG1 was
able to suppress RhoA activity, whereas antisense RRIG1
promoted RhoA activity in these breast cancer cells
(Figure 4C). Because a recent study reported that the
MDA-MB-435 cell line may have originated from mela-
noma cells [10,11], we added another RRIG1-positive cell
line for antisense RRIG1 transfection. Antisense RRIG1
cDNA reduced RRIG1 mRNA levels but did not affect
expression of SH3 domain GRB2-like endophilin B2
(SH3GLB2) (Figure 5). Knockdown of RRIG1 expression
enhanced cell viability and invasion capacity of T47D cells
(Figure 5).
Figure 1 Immunohistochemical analysis of RRIG1 expression. Breast tissue sections were immunostained with the rabbit polyclonal anti-
RRIG1 antibody. DCIS, ductal carcinoma in situ.
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Discussion
In the current study, we analyzed RRIG1 expression in
breast tissue specimens and then determined the role of
RRIG1 in breast cancer cells. We found that RRIG1
expression is reduced in breast cancer tissues, as
reported by us previously [7]. RRIG1 expression was
inversely correlated with lymph node metastasis of
breast cancer. Furthermore, the restoration of RRIG1
expression in a breast cancer cell line resulted in tumor-
suppressor activities, such as inhibition of tumor cell
proliferation, colony formation, migration, and invasion.
At molecular levels, RRIG1 suppressed expression of
p-Erk1/2, p-Akt, total Akt, c-Jun, and MMP9 and RhoA
activity. These genes are related to cell growth, adhe-
sion, and mobility. However, knockdown of RRIG1
expression in another breast cancer cell line promoted
tumor cell proliferation, colony formation, migration,
and invasion, but these effects were associated with reg-
ulation of p-Stat3, p-Rb, and E2F-1.This study suggests
that RRIG1 plays a role in suppressing breast cancer
progression or even development of breast cancer.
Our previous studies [5-7] demonstrated that RRIG1
is a novel gene and may be a putative tumor suppressor.
RRIG1 gene contains 6 exons, with exons 2, 3, and 5
shared with exons 8, 9, and 10 of SH3GLB2 cDNA [7].
However, the open reading frames of these two genes
are different, and therefore they are different genes.
Moreover, our study also revealed that these two genes
were differentially expressed in esophageal and prostate
cancer cell lines [5,8] and that benzo[a]pyrene diol
epoxide (BPDE) reduced RRIG1 expression but did not
alter SH3GLB2 mRNA levels in esophageal cancer cell
lines (our unpublished data). These findings indicate
that RRIG1 is a novel protein with no similarities to
other proteins and that RRIG1 protein contains several
putative functional motifs, such as a cadherin signature-
like motif, a glycoprotein GG/GX motif, and proline-
rich regions that contain SH3 domain-binding motifs
(PxxP). The latter motif was able to functionally mediate
RRIG1 antitumor activity by suppressing tumor cell via-
bility and cyclin D1 expression [7]. Nevertheless, it is
unclear whether knockdown of RRIG1 expression using
a vector carrying antisense open reading frame of
RRIG1 can block expression of SH3GLB2 protein
(Because no anti-SH3GLB2 antibody is available, we
could not perform such an experiment). However, our
current study showed that the vector carrying antisense
open reading frame of RRIG1 did not affect expression
of SH3GLB2 mRNA (Figure 5).
Our current and previous studies clearly demonstrated
that reduced or lost expression of RRIG1 is an impor-
tant event in the development or progression of human
cancers, although the mechanism underlying the loss of
expression of the RRIG1 gene remains unknown [5-8].
Moreover, our previous studies [12-14] reported that
benzo[a]pyrene diol epoxide (BPDE), a carcinogen pre-
sent in tobacco smoke and environmental pollution, as
well as bile acid, a tumor promoter in the gastrointest-
inal tract, inhibited RRIG1 expression, whereas retinoic
acid induced RRIG1 expression, which was associated
with downregulation of RAR-b2 expression by these car-
cinogens. In addition, previous studies demonstrated a
loss of RAR-b2 expression in breast cancer tissues and
cells [15-17]. Further study will be needed to determine
the molecular mechanism that contributes to the loss of
RRIG1 expression and, most importantly, to define
RRIG1 as a tumor-suppressor gene in the inhibition of
tumor cell growth, invasion, and gene expression.
Our current study demonstrated that the restoration
ofRRIG1 expression inhibited breast cancer cell prolif-
eration,colony formation, migration, and invasion and
regulated geneexpression. Inhibition of phosphorylated
Erk1/2 and Akt and c-Junexpression by RRIG1 may
mediate RRIG1 suppression of cell growth, while
reduced MMP9 expression by RRIG1 mediates the
reduced tumor cell mobility and invasion capacity. Our
previous study showed that MMP9 was upregulated in
breast cancer [18]. Erk1/2 and Akt proteins play an
Table 1 Association of RRIG1 expression with
clinicopathologic features of breast cancer patients
Variable RRIG1 expression
Positive Negative p Value
Patient age (years) 0.30
≤ 35 3 0
35-55 34 17
> 55 13 10
Tumor size (cm) 0.66
≤ 2 8 3
2-5 32 20
> 5 10 4
Lymph node metastasis 0.01
+ 22 20
_ 28 7
Tumor differentiation 0.18
I 16 5
II 27 14
III 7 8
Estrogen receptor 0.64
+ 25 15
- 25 12
Progesterone receptor
+ 27 15 0.89
- 23 12
c-erbB-2 0.62
+ 14 9
- 36 18
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Figure 2 RRIG1 expression and modulation of breast cancer cell growth and colony formation. All experiments were repeated once with
similar results. A, Semiquantitative RT-PCR. Breast cancer cell lines were grown in monolayer, and RNA was then isolated from the cells and
subjected to semiquantitative RT-PCR analysis of RRIG1 expression. B, Semiquantitative RT-PCR.pCDNA3.1 carrying RRIG1 sense and antisense
cDNA was transiently transfected into MDA-MB-231 and MDA-MD-435 cells, respectively. The vector-only plasmid was used as a control. The cells
were grown in G418-containing medium, and RNA from the cells was isolated and subjected to semiquantitative RT-PCR analysis. C, Cell viability
assay. The gene-transfected cells were grown in G418-containing medium for 1 or 5 days, and cell viability was measured using the MTT assay.
D, Colony formation assay. The gene-transfected cells were grown in soft agar with G418-containing medium for 21 days, and cell colonies were
then visualized by incubation with MTT, counted, and summarized. *p < 0.05 vs. the control.
Zhang et al. BMC Cancer 2011, 11:32
http://www.biomedcentral.com/1471-2407/11/32
Page 7 of 12
important role in cell survival, and activation of Akt has
been shown to overcome cell cycle arrest in G1 and G2
phases of the cell cycle to enable cell proliferation
[19-22]. Nevertheless, knockdown of RRIG1 expression
has had opposite effects in the regulation of breast cancer
cell growth, colony formation, migration, and invasion.
Interestingly, these effects were through RRIG1 regula-
tion of some other gene expressions, such as phosphory-
lated Stat3 and Rb. A previous study has shown the
retinoic acid suppressed Stat3 phosphorylation in skin
cancers [23]. Stat3 is a transcriptional factor and med-
iates expression of a variety of genes in response to cell
stimuli and thus plays a key role in many cellular pro-
cesses such as cell growth and apoptosis [24,25]. RRIG1
protein contains two putative Src homology 3 (SH3)
domain-binding motifs that were characterized in a
previous study [26], and our preliminary data showed
that RRIG1 was able to bind to Src protein [8]. Previous
studies [see reviews in ref. [25]] demonstrated that the
role of STAT3 as a downstream signal transducer in Src
family kinase-mediated tumorigenesis suggests that
RRIG1 may suppress Stat3 activity through binding to
Src protein. However, this needs further investigation.
Furthermore, our current study also confirmed our
previous finding that RRIG1 inhibits RhoA activation to
execute some of its biological functions [5]. RhoA is a
small GTPase protein known to regulate the actin cytos-
keleton in controlling cell mobility and growth and
modulating gene expression [27-31]. The aberrant acti-
vation of RhoA proteins was found to cause cell growth,
transformation, invasion, and metastasis in experimental
models of carcinogenesis, and inhibition of RhoA
Figure 3 Tumor cell migration and invasion assays. All experiments were performed in triplicate and repeated twice. A, Migration assay. The
RRIG1 sense and antisense-transfected MDA-MB-231 and MDA-MB-435 cells, respectively, were grown in G418-containing medium and then
subjected to cell migration assay in Boyden chambers without Matrigel for 24 h. The cells that migrated were stained with 1% crystal violet
solution and then counted and summarized. B, Invasion assay. These gene-transfected breast cancer cells were grown in G418-containing
medium and then subjected to the cell invasion assay in Boyden chambers with Matrigel for 48 h. The invaded cells were stained with 1%
crystal violet solution and then counted and summarized. *p < 0.05 vs. the control.
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Figure 4 RRIG1 regulation of gene expression and activities. All the experiments were repeated at least once with similar results. A, Western
blotting. The RRIG1 sense and antisense-transfected MDA-MB-231 and MDA-MB-435 cells, respectively, were grown in G418-containing medium
for 5 days and then subjected to protein extraction and western blotting analysis of gene expression. The value shown is the percentage of
control, which was calculated using the formula: value of the RRIG1 sense or antisense transfected cells/value of the vector-only transfected cells
after intensity of the target band of proteins from western blots was quantified by using NIH ImageJ 1.34s software and normalized to b-actin.
B, Semiquantitative RT-PCR. The gene-transfected cells were grown in G418-containing medium for 5 days, and RNA was then isolated from the
cells and subjected to semiquantitative RT-PCR analysis of MMP9 expression. C, RhoA activation assay. The gene-transfected cells were grown in
G418-containing medium for 5 days and then subjected to the RhoA activation and western blot assays. The data were quantified using the NIH
ImageJ software.
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suppressed cell proliferation, invasion, and angiogenesis
in vitro and in vivo [27-31]. The RRIG1 protein can
bind to the RhoA protein, although it is unknown
whether this binding is direct or indirect [5]. We studied
the RRIG1 and RhoA association because, in our unpub-
lished findings of an in vitro pull-down assay, RRIG1
protein was able to pull down RhoA protein.
Conclusion
Our current study clearly showed the importance of
lower RRIG1 expression in breast cancer cell growth,
colony formation, invasion, and altered gene expression.
Future study will attempt to determine the underlying
molecular mechanisms and define RRIG1 as a tumor-
suppressor gene in breast cancer.
Figure 5 The effects of antisense RRIG1 in breast cancer T47D cells. All experiments were repeated at least once with similar results. A,
Semiquantitative RT-PCR. The gene-transfected cells were grown in G418-containing medium for 5 days, and RNA was then isolated from the
cells and subjected to semiquantitative RT-PCR analysis of RRIG1, SH3GLB2, and GAPDH expression. B, MTT assay. The gene-transfected cells were
grown in G418-containing medium for 1 or 5 days, and cell viability was measured using the MTT assay. C, Invasion assay. These gene-
transfected breast cancer cells were grown in G418-containing medium and then subjected to the cell invasion assay in Boyden chambers with
Matrigel for 48 h. The invaded cells were stained with 1% crystal violet solution and then counted and summarized. Vec, vector-only; AS,
antisense RRIG1 cDNA; *p < 0.05 vs. the control.
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Additional material
Additional File 1: Figure S1: Specificity of rabbit polyclonal anti-
RRIG1 antibody for immunohistochemistry. A, Western blot. RRIG1
protein was first in vitro translated with pGEM and pcDNA3.1 vectors-
carrying RRIG1 open-reading frame cDNA and an in vitro protein
translation kit. The samples from the in vitro translation were subjected
to western blot analysis of RRIG1 expression using our polyclonal anti-
RRIG1 antibody. NC, negative control. B, Western blot. Esophageal cancer
TE-8S22 and prostate cancer PC3 cells were grown on monolayer for 3
days and total cellular protein was extracted and subjected to western
blot with the polyclonal anti-RRIG1 antibody. The vector controlled in
vitro translational sample was used for negative control. NC, negative
control. NS, non-specific. C, Immunohistochemistry. RRIG-1-negative
esophageal cancer cells TE-8 and RRIG-1 stably transfected TE-8-RRIG1
cells were grown in organotypic cultures for 14 days and the 3-D cell
layers were subjected to tissue processing and immunohistochemistry
with the polyclonal anti-RRIG1 antibody. D, Expression of RRIG1 mRNA
and protein in breast tissues using in situ hybridization (ISH, see ref. 5 for
the detailed methodology) and immunohistochemistry (IHC). Additional
Method Organotypic culture. Esophageal cancer cell lines TE-8 and TE-
8-RRIG1 were seeded on to collagen gels prepared by using type I rat-
tail collagen (Collaborative Biomedical Products, Bedford, MA), and
incubated overnight until the cells will be confluent. The gels were then
elevated to the air-liquid interface by placing them onto a surgical
stainless steel mesh platform. DMEM was added until it reached the
undersurface of the collagen gel but not cover the cell layer. The
cultures were incubated at 37°C for 2 weeks after elevation to the air-
medium interface. In the end of the experiments, the cell discs were
fixed in 4% paraformaldehyde and embedded in paraffin following by
sectioning and staining.
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